- Home
- GENK vs ACXP Comparison
GENK vs ACXP Comparison
Compare GENK & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- ACXP
- Stock Information
- Founded
- GENK 2011
- ACXP 2017
- Country
- GENK United States
- ACXP United States
- Employees
- GENK N/A
- ACXP N/A
- Industry
- GENK Restaurants
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- ACXP Health Care
- Exchange
- GENK Nasdaq
- ACXP Nasdaq
- Market Cap
- GENK 20.4M
- ACXP 8.4M
- IPO Year
- GENK 2023
- ACXP 2021
- Fundamental
- Price
- GENK $3.89
- ACXP $0.49
- Analyst Decision
- GENK Strong Buy
- ACXP Strong Buy
- Analyst Count
- GENK 2
- ACXP 2
- Target Price
- GENK $10.00
- ACXP $10.00
- AVG Volume (30 Days)
- GENK 59.5K
- ACXP 18.6M
- Earning Date
- GENK 07-30-2025
- ACXP 08-08-2025
- Dividend Yield
- GENK 0.77%
- ACXP N/A
- EPS Growth
- GENK N/A
- ACXP N/A
- EPS
- GENK N/A
- ACXP N/A
- Revenue
- GENK $214,957,000.00
- ACXP N/A
- Revenue This Year
- GENK $16.62
- ACXP N/A
- Revenue Next Year
- GENK $20.40
- ACXP N/A
- P/E Ratio
- GENK N/A
- ACXP N/A
- Revenue Growth
- GENK 14.40
- ACXP N/A
- 52 Week Low
- GENK $3.16
- ACXP $0.30
- 52 Week High
- GENK $10.33
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- GENK 49.06
- ACXP 51.01
- Support Level
- GENK $3.50
- ACXP $0.46
- Resistance Level
- GENK $4.07
- ACXP $0.56
- Average True Range (ATR)
- GENK 0.24
- ACXP 0.10
- MACD
- GENK 0.02
- ACXP -0.01
- Stochastic Oscillator
- GENK 57.35
- ACXP 24.27
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.